Incannex Healthcare Australian Stock Exchange




Market Closed - Australian Stock Exchange 12:10:13 2023-11-17 am EST Intraday chart for Incannex Healthcare 5-day change 1st Jan Change
0.041 AUD -10.87% -.--% -76.57%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Chart Incannex Healthcare
More charts
Incannex Healthcare Limited is an Australia-based clinical-stage pharmaceutical development company. The Company is engaged in the research and development associated with medicinal cannabinoid and psychedelic pharmaceutical products and therapies. The Company targets five indications: obstructive sleep apnea (OSA), traumatic brain injury and concussion (TBI), rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and inflammatory lung conditions. Its drug candidates include IHL-42X, IHL-216A, Psilocybin-assisted psychotherapy for general anxiety disorder (Psi-GAD) and IHL-675A. Its IHL-42X is a cannabinoid combination product for treatment of OSA. Its IHL-675A comprises a combination of hydroxychloroquine and CBD for prevention and treatment of inflammatory lung conditions, rheumatoid arthritis and inflammatory bowel diseases. IHL-216A is a cannabinoid combination product for the treatment of TBI. It is investigating the use of psilocybin-assisted psychotherapy to treat GAD.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Incannex Healthcare Inc.
  4. Stock Incannex Healthcare - Australian Stock Exchange
  5. News Incannex Healthcare
  6. Incannex Opens Patient Registration for Psychedelics-Assisted Treatment Program; Shares Rise 5%
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits